Inoxgen (Nitric Oxide)

Nitric oxide released from Inoxgen activates soluble guanylate cyclase in pulmonary smooth‑muscle cells, increasing cyclic GMP levels. This biochemical cascade leads to relaxation of the smooth muscle, causing vasodilation of the pulmonary arteries and a reduction in pulmonary vascular resistance.

The dose of Inoxgen is individualized and set by the prescribing clinician based on the patient’s age, weight, severity of pulmonary hypertension, and response to therapy. Administration is typically titrated using continuous hemodynamic monitoring.

Safety data for Inoxgen in pregnancy and lactation are limited. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when possible. The decision should be made on a case‑by‑case basis by the treating physician.

To place an order, submit an enquiry on the Inoxgen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Inoxgen delivers nitric oxide directly to the lungs, providing rapid and selective pulmonary vasodilation with minimal systemic effects. Compared with oral phosphodiesterase‑5 inhibitors, it offers immediate titration but requires specialized delivery equipment and careful monitoring for rebound hypertension upon discontinuation.

Inoxgen should be stored at ambient temperature, kept upright in its original cylinder, protected from heat, direct sunlight, and moisture. Ensure proper ventilation in the storage area and follow local regulations for handling compressed medical gases.

Inoxgen is administered via endotracheopulmonary inhalation using a calibrated delivery system that mixes the gas with the patient’s inspired air. The concentration is adjusted in real time based on continuous monitoring of oxygenation and pulmonary artery pressures.

The most serious risks include severe systemic hypotension, rebound pulmonary hypertension after abrupt cessation, methemoglobinemia, and bleeding complications, especially when used with anticoagulants or antiplatelet agents. Close monitoring is essential to detect and manage these events promptly.

Inoxgen is contraindicated in patients with known hypersensitivity to nitric oxide or its delivery system, those with severe left‑ventricular dysfunction where systemic hypotension could be hazardous, and individuals receiving other potent vasodilators without appropriate monitoring.